Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 05, 2021 08:00 ET | Source: VBL Therapeutics

VBL Therapeutics Announces Appointment of Sam Backenroth as Chief Financial Officer and Establishes Operations in the United States

TEL AVIV, Israel and NEW YORK, Oct. 05, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced the appointment of Sam Backenroth as chief financial officer (CFO) effective...
September 17, 2021 07:00 ET | Source: VBL Therapeutics

VBL Therapeutics Announces Independent Data Safety Monitoring Committee Provides Clearance to Continue the OVAL Phase 3 Registration-Enabling Study of VB-111 in Ovarian Cancer

The OVAL Phase 3 clinical trial evaluating VB-111 in platinum-resistant ovarian cancer has recruited more than 320 patients (>80 %) to date;Remains on track to complete enrollment in 1Q22 TEL...
September 10, 2021 07:00 ET | Source: VBL Therapeutics

VBL Therapeutics to Present at Upcoming Conferences

TEL AVIV, Israel, Sept. 10, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ: VBLT) today announced the Company will present in the following upcoming industry conferences: H.C. Wainwright 23rd...
August 30, 2021 07:00 ET | Source: VBL Therapeutics

VBL Therapeutics Resumes U.S. Enrollment in OVAL Phase 3 Trial as FDA Authorizes Clinical Use of VB-111 Batches Produced in Modiin Facility

U.S. FDA CMC clearance of VB-111 produced in Modiin, Israel facility an important milestone toward potential commercializationOVAL Phase 3 trial evaluating VB-111 in platinum resistant ovarian cancer...
August 16, 2021 07:00 ET | Source: VBL Therapeutics

VBL Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update

Conference Call and Webcast at 8:30 a.m. EDT Today ● Closed public offering raising net proceeds of $26.4 million; cash position is expected to fund operations until year-end 2023, through readout...
August 05, 2021 07:00 ET | Source: VBL Therapeutics

VBL Therapeutics to Report Second Quarter Financial Results on August 16

TEL AVIV, Israel, Aug. 05, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) will release its second quarter financial results for the period ended June 30, 2021 on Monday, August 16 before...
July 22, 2021 07:00 ET | Source: VBL Therapeutics

VBL Therapeutics Appoints Marc Kozin as Chairman of its Board of Directors

TEL AVIV, Israel, July 22, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced the planned elevation of Marc Kozin as chairman of the company’s board of directors. Bennett...
July 08, 2021 07:00 ET | Source: VBL Therapeutics

VBL Therapeutics Appoints Alison Finger and Michael Rice to its Board of Directors

TEL AVIV, Israel, July 08, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced the appointments of Alison Finger and Michael Rice to its Board of Directors, effective July 7,...
June 15, 2021 07:00 ET | Source: VBL Therapeutics

VBL Therapeutics Provides Update on OVAL, a Phase 3 Registration Enabling Study of VB-111 in Ovarian Cancer

TEL AVIV, Israel, June 15, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today provided an update on its ongoing OVAL Phase 3 study investigating ofranergene obadenovec (VB-111), for the...
June 03, 2021 07:00 ET | Source: VBL Therapeutics

VBL Therapeutics Announces Addition of Progression Free Survival as a Second Primary Endpoint in OVAL, a Phase 3 Registration Enabling Study of VB-111 in Ovarian Cancer

Second primary endpoint added following discussion with the U.S. Food and Drug AdministrationSuccessfully meeting either PFS or OS primary endpoints expected to be sufficient for submitting a BLA for...